TY - JOUR
T1 - Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
AU - Kittur, Jaya
AU - Knudson, Ryan A.
AU - Lasho, Terra L.
AU - Finke, Christy M.
AU - Gangat, Naseema
AU - Wolanskyj, Alexandra P.
AU - Li, Chin Yang
AU - Wu, Wenting
AU - Ketterling, Rhett P.
AU - Pardanani, Animesh
AU - Tefferi, Ayalew
PY - 2007/6/1
Y1 - 2007/6/1
N2 - BACKGROUND. JAK2V617F occurs in approximately 50% of patients with essential thrombocythemia (ET). Qualitative studies of mutation analysis have previously reported an association between JAK2V617F and advanced age, higher hemoglobin level, higher leukocyte count, and lower platelet count. A possible association with thrombotic complication has also been considered. METHODS. Allele-specific, quantitative polymerase chain reaction (PCR) analysis for JAK2V617F was performed in 176 patients with ET using genomic DNA from archived bone marrow, which was collected within 1 year (n = 72 patients), between 1 and 5 years (n = 64 patients), or after 5 years (n = 40 patients) of diagnosis. RESULTS. JAK2V617F was detected in 96 patients (55%), in whom mutant allele burden ranged from 1% to 100% (median, 6.3%). Neither mutational frequency (P = .37) nor mutant allele burden (P = .62) was affected by the timing of bone marrow sample collection. The presence of JAK2V617F was found to be significantly associated with higher hemoglobin level (P < .0001), lower platelet count (P = .001), higher leukocyte count (P = .008), increased incidence of venous thrombosis occurring after diagnosis (P = .02), and older age at diagnosis (P = .03). All but age retained significance in multivariable analysis. In mutation-positive patients (n = 96 patients), JAK2V617F allele burden clustered between 1% and 22% in 94 cases, in whom it correlated directly and significantly with platelet and leukocyte counts, palpable splenomegaly at diagnosis, and venous thrombosis occurring after diagnosis. The latter 2 associations remained significant with the inclusion of the remaining 2 outlier cases with 100% mutant allele burden; in addition, an association with male gender became evident. CONCLUSIONS. JAK2V617F allele burden imparts additional phenotypic effects in ET.
AB - BACKGROUND. JAK2V617F occurs in approximately 50% of patients with essential thrombocythemia (ET). Qualitative studies of mutation analysis have previously reported an association between JAK2V617F and advanced age, higher hemoglobin level, higher leukocyte count, and lower platelet count. A possible association with thrombotic complication has also been considered. METHODS. Allele-specific, quantitative polymerase chain reaction (PCR) analysis for JAK2V617F was performed in 176 patients with ET using genomic DNA from archived bone marrow, which was collected within 1 year (n = 72 patients), between 1 and 5 years (n = 64 patients), or after 5 years (n = 40 patients) of diagnosis. RESULTS. JAK2V617F was detected in 96 patients (55%), in whom mutant allele burden ranged from 1% to 100% (median, 6.3%). Neither mutational frequency (P = .37) nor mutant allele burden (P = .62) was affected by the timing of bone marrow sample collection. The presence of JAK2V617F was found to be significantly associated with higher hemoglobin level (P < .0001), lower platelet count (P = .001), higher leukocyte count (P = .008), increased incidence of venous thrombosis occurring after diagnosis (P = .02), and older age at diagnosis (P = .03). All but age retained significance in multivariable analysis. In mutation-positive patients (n = 96 patients), JAK2V617F allele burden clustered between 1% and 22% in 94 cases, in whom it correlated directly and significantly with platelet and leukocyte counts, palpable splenomegaly at diagnosis, and venous thrombosis occurring after diagnosis. The latter 2 associations remained significant with the inclusion of the remaining 2 outlier cases with 100% mutant allele burden; in addition, an association with male gender became evident. CONCLUSIONS. JAK2V617F allele burden imparts additional phenotypic effects in ET.
KW - Allele burden
KW - Essential thrombocythemia
KW - JAK2V617F
UR - http://www.scopus.com/inward/record.url?scp=34249071097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249071097&partnerID=8YFLogxK
U2 - 10.1002/cncr.22663
DO - 10.1002/cncr.22663
M3 - Article
C2 - 17440984
AN - SCOPUS:34249071097
SN - 0008-543X
VL - 109
SP - 2279
EP - 2284
JO - Cancer
JF - Cancer
IS - 11
ER -